TG Therapeutics (TGTX) Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in MS to be Presented at American Academy of Neurology 73rd Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
Go back to TG Therapeutics (TGTX) Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in MS to be Presented at American Academy of Neurology 73rd Annual Meeting
April 16, 2021 7:30 AM EDT
Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Ublituximab was generally well tolerated, with no unexpected safety signals
BLA submission targeted in Q3 2021
Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET
NEW YORK, April... More